The FDA wants to “pre-check” factories before the medicine exists
On February 1, 2026, the U.S. Food and Drug Administration
Obesity’s next arms race: staying power, not just weight loss
The GLP-1 era has changed what patients and investors think
The GLP-1 pill arrives: Novo’s oral Wegovy reshapes the obesity market
On December 22, 2025, the U.S. Food and Drug Administration
The obesity wars go to court: Pfizer says Novo’s Metsera bid is a moat, not a merger
As the GLP-1 gold rush enters its most aggressive phase,
Galapagos quits cell therapy. Europe’s CGT reckoning begins.
Late on Monday night in California — 10:30 p.m. PT
Dermatology’s next play: bispecifics that shut down OX40L and TNF
Pairing a T-cell co-stimulatory brake with an inflammatory workhorse is
From Hope to Proof: How Prasad’s FDA Could Reshape Biotech Approvals
When Dr. Vinay Prasad was abruptly removed from his FDA
AbbVie Enters Obesity Drug Market with $2.2B Gubra Licensing Deal
AbbVie, a leading biopharmaceutical company, has taken a significant step
Metsera’s Weight-Loss Drug MET-097i Shows Strong Clinical Results
Obesity remains a critical public health challenge in the United
Light-Based Microcapillary Monitoring Expands Precision in Biotechnology
Microcapillary technology, particularly light-based microcapillary monitoring, represents a significant advancement
Novo Holdings Leads $100 Million Series C Financing for Asceneuron
Novo Holdings has led a $100 million Series C financing
Myricx Bio’s NMTi-ADCs Achieve Tumor Regression in Preclinical Trials
The field of cancer treatment is on the cusp of
Illumina Faces Potential $7 Billion Loss from Forced Grail Sale: An Analysis
1. Introduction Background on Illumina and Grail Illumina, Inc. is
EU Sets New Goals for Advancing Biotechnology and Biomanufacturing
job louana237 Executive Summary The EU Biotech and Biomanufacturing Initiative
AI-Powered Drug Repurposing by BioXcel Therapeutics Accelerates Development of New Neuropsychiatric Treatments
1. Introduction BioXcel Therapeutics is a biopharmaceutical company leveraging artificial
AstraZeneca Completes Equity Investment in Cellectis to Enhance Gene Therapy Development
AstraZeneca has completed its planned equity investment in Cellectis, a
MOST POPULAR
